The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells
Open accessAbstract
BACKGROUND: Glioblastoma multiforme (GBM) cells are resistant to anticancer drugs. Cancer stem cells (CSCs) are a key mediator of chemoresistance. We have reported that disulfiram (DS), an aldehyde dehydrogenase (ALDH) inhibitor, targets breast CSC-like cells. In this study, the effect of DS and combination of DS and gemcitabine (dFdC) on GBM cells and GBM stem-like cells was investigated. METHODS: 1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT), combination index (CI)-isobologram, western blot, luciferase reporter gene assay, electrophoretic mobility-shift assay and ALDH analysis were used in this study. RESULTS: Disulfiram is cytotoxic in GBM cell lines in a copper (Cu)-dependent manner. Disulfiram/copper enhances the cytotoxicity of dFdC. Combination index-isobologram analysis indicates a synergistic effect between DS/Cu and dFdC. Disulfiram/copper induces reactive oxygen species (ROS), activates JNK and p38 pathways and inhibits nuclear factor-kappa B activity in GBM cell lines. Disulfiram/copper may trigger intrinsic apoptotic pathway via modulation of the Bcl2 family. Disulfiram/copper abolishes stem-like cell population in GBM cell lines. CONCLUSION: Our findings indicate that the cytotoxicity of DS/Cu and the enhancing effect of DS/Cu on the cytotoxicity of dFdC in GBM stem-like cells may be caused by induction of ROS and inhibition of both ALDH and the NFkB pathway. Both DS and dFdC can traverse the blood-brain barrier. Further study may lead them into GBM chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
Mechanisms for copper acquisition, distribution and regulation
Kim, B.-E., Nevitt, T., & Thiele, D. J. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.72 · Cited by 1,588
NF-κB activation by reactive oxygen species: Fifteen years later
Gloire, G., Legrand-Poels, S., & Piette, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.04.011 · Cited by 1,537
Aberrant rel/nfkb genes and activity in human cancer
Rayet, B., & Gélinas, C. (1999) · Oncogene · doi:10.1038/sj.onc.1203221 · Cited by 1,110
Elevated copper and oxidative stress in cancer cells as a target for cancer treatment
Gupte, A., & Mumper, R. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.07.004 · Cited by 1,036
Vescovi, A. L., Galli, R., & Reynolds, B. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1889 · Cited by 990
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 983
Cited by
Copper homeostasis and cuproptosis in health and disease
Chen, L., Min, J., & Wang, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01229-y · Cited by 1,493
Copper metabolism in cell death and autophagy
Xue, Q., Kang, R., Klionsky, D. J., Tang, D., Liu, J., & Chen, X. (2023) · Autophagy · doi:10.1080/15548627.2023.2200554 · Cited by 701
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
The multifaceted role of reactive oxygen species in tumorigenesis
Kirtonia, A., Sethi, G., & Garg, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03536-5 · Cited by 452
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance
Wang, Y., Chen, Y., Zhang, J., Yang, Y., Fleishman, J. S., Wang, Y., Wang, J., Chen, J., Li, Y., & Wang, H. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101018 · Cited by 256
Lun, X., Wells, J. C., Grinshtein, N., King, J. C., Hao, X., Dang, N.-H., Wang, X., Aman, A., Uehling, D., Datti, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1798 · Cited by 197
Small molecules regulating reactive oxygen species homeostasis for cancer therapy
Zhang, J., Duan, D., Song, Z., Liu, T., Hou, Y., & Fang, J. (2021) · Medicinal Research Reviews · doi:10.1002/med.21734 · Cited by 184
Lu, Y., Pan, Q., Gao, W., Pu, Y., Luo, K., He, B., & Gu, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121335 · Cited by 149
Disulfiram’s anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase
Skrott, Z., Majera, D., Gursky, J., Buchtova, T., Hajduch, M., Mistrik, M., & Bartek, J. (2019) · Oncogene · doi:10.1038/s41388-019-0915-2 · Cited by 115
Chemical approaches to targeting drug resistance in cancer stem cells
Sotiropoulou, P. A., Christodoulou, M. S., Silvani, A., Herold-Mende, C., & Passarella, D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.002 · Cited by 100
The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells
Tawari, P. E., Wang, Z., Najlah, M., Tsang, C. W., Kannappan, V., Liu, P., McConville, C., He, B., Armesilla, A. L., & Wang, W. (2015) · Toxicology Research · doi:10.1039/c5tx00210a · Cited by 86
Self-citationHuang, J., Campian, J. L., Gujar, A. D., Tran, D. D., Lockhart, A. C., DeWees, T. A., Tsien, C. I., & Kim, A. H. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2104-2 · Cited by 79
Huang, J., Campian, J. L., Gujar, A. D., Tsien, C., Ansstas, G., Tran, D. D., DeWees, T. A., Lockhart, A. C., & Kim, A. H. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2775-y · Cited by 52
Du, C., Guan, X., Liu, Y., Xu, Z., Du, X., Li, B., Wang, M., & Zheng, Z. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04398-3 · Cited by 36
Huang, J., Campian, J. L., DeWees, T. A., Skrott, Z., Mistrik, M., Johanns, T. M., Ansstas, G., Butt, O., Leuthardt, E., Dunn, G. P., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.05.009 · Cited by 34
Li, H., Liu, B., Ao, H., Fu, J., Wang, Y., Feng, Y., Guo, Y., & Wang, X. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0565-0 · Cited by 28
Lu, X., Lin, B., Xu, N., Huang, H., Wang, Y., & Lin, J.-M. (2020) · Talanta · doi:10.1016/j.talanta.2020.120732 · Cited by 23
Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study
Zirjacks, L., Stransky, N., Klumpp, L., Prause, L., Eckert, F., Zips, D., Schleicher, S., Handgretinger, R., Huber, S. M., & Ganser, K. (2021) · Biomolecules · doi:10.3390/biom11111561 · Cited by 16
Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation
Meier, S., Cantilena, S., Niklison Chirou, M. V., Anderson, J., Hargrave, D., Salomoni, P., de Boer, J., & Michod, D. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04078-9 · Cited by 15
Repurposing disulfiram to induce OSCC cell death by cristae dysfunction promoted autophagy
Wang, Z., Jiang, H., Cai, L., Ji, N., Zeng, X., Zhou, Y., Shen, Y., & Chen, Q. (2021) · Oral Diseases · doi:10.1111/odi.13652 · Cited by 15
Tang, C., Pang, X., Guo, Z., Guo, R., Liu, L., & Chen, X. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000317 · Cited by 14
Metadata
- Authors
- Liu, P., Brown, S., Goktug, T., Channathodiyil, P., Kannappan, V, Hugnot, J.-P., Guichet, P.-O., Bian, X., Armesilla, A. L., Darling, J. L., & Wang, W.
- Venue
- British Journal of Cancer
- Published
- 2012-10
- Volume
- 107
- Issue
- 9
- Pages
- 1488-1497
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2007369931
- Cited by
- 300
- References
- 50
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.